Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2021 - 10 - 14 save search
Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer
Published: 2021-10-14 (Crawled : 18:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.2%
H: 0.08%
C: -0.43%
lung cancer cancer therapy
Hoag First Hospital in Orange County to Enroll Patients in NK Cell Therapy Clinical Trial for Triple-Negative Breast Cancer Patients
Published: 2021-10-14 (Crawled : 18:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
therapy cancer breast cancer trial enroll
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.99%
H: 8.76%
C: 4.24%
treatment phase 2 cancer pancreatic pancreas enroll
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: 0.91%
H: 0.99%
C: 0.9%
new drug fda fda acceptance phase 1 cancer drug license trial
Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
LH M | $207.97 2.41% 0.0% 930K
|
Health Services
|
| O: 0.82%
H: 0.83%
C: 0.0%
test genomic cancer bioscience collaboration
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Published: 2021-10-14 (Crawled : 12:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 1.42%
H: 3.26%
C: 1.86%
chinese treatment cancer biotech iot breast cancer trial
HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
HOOK | $0.7801 10.34% 9.37% 790K
|
Health Technology
|
| O: 2.98%
H: 1.99%
C: -1.81%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.86%
H: 0.76%
C: -0.09%
cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.